BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity (Tables)

6 Months Ended

Jun. 30, 2020

	Six months ended June 30,
	2020		2019

Underlying value of share of Common Stock ($)		5.59-6.21		4.91
Exercise price ($)		5.59-6.21		4.91
Expected volatility (%)		85.0		93.1
Term of the option (years)		6.25		6.25
Risk-free interest rate (%)		0.37-0.52		2.23

	For the six months ended June 30, 2020
	Number of Options			Weighted average exercise price		Aggregate intrinsic value
				USD		USD in thousands
Outstanding at the beginning of period		3,143,802			1.09		25,733
Granted		893,700			6.16
Forfeited		(41,925	)		2.45
Exercised		(277,429	)		0.63
Outstanding at the end of period		3,718,148			3.08		10,484
Vested at end of period		1,641,346
Weighted average remaining contractual life – years as of June 30, 2020		6.92

Warrant

Issuance Date

Expiration Date

Exercise Price
Per Share (USD)

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to Yeda (see 1 below)

May 11, 2017

May 11, 2025

)

591,382

Private Warrants issued to founders (see 2 below)

November 27, 2017

10,589

Private Placement Warrants (see 3 below)

IPO

(December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants (see 4 below)

IPO

(December 13, 2018)

October 28,

2024

11.50

3,500,000

7,001,971

(*)	less than $0.001.

	Six months ended June 30,
	2020		2019

Research and development expenses, net		502		367
General and administrative		512		264
		1,014		631

	Three months ended June 30,
	2020		2019

Research and development expenses, net		310		173
General and administrative		367		154
		677		327